UNISTAC
Live / Registered — Registered (as of 10 Oct 2023)
What this means for you
Registered since 10 Oct 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79321390
- Registration number
- 7184963
- Mark type
- Stylized text
- Filed
- 06 Aug 2021
- Published for opposition
- 21 Feb 2023
- Registered
- 10 Oct 2023
- Attorney of record
- Connie L. Ellerbach
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; cardiovascular treatment preparations; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; antibacterial pharmaceuticals; pharmaceutical drugs being pharmaceutical preparations namely, for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; synthetic peptides for pharmaceutical purposes namely, for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; pharmaceutical compositions for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; clinical medical reagents; clinical diagnostic reagents for medicinal use; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for use in tissue transplantation; tissue-regenerative pharmaceutical preparations; pharmaceutical preparations for tumor treatment; stimulants for the central nervous system; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for treating respiratory diseases
- Class 042 — Scientific and technological services: Research and development of vaccines and medicines; research and development of technology for biotechnology; development of biotechnology; research relating to biotechnology; laboratory research in the field of biology; biological research services; development of new technologies in the field of biologics; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; research in the field of pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs; pharmaceutical drug development services; pharmaceutical research and development; research relating to pharmaceuticals; scientific research in the field of pharmacy; medical laboratory services; research relating to new technologies for medical treatment; medical research laboratory services; scientific research for medical purposes in the area of cancerous diseases; research and development of new technologies for others in the field of amino acid for medical purpose; research and development of new technologies for others in the field of peptide for medical purposes; research and development of technology for medicinal chemical manufacturing; medicine research; scientific research relating to medical substances; medical research; scientific research relating to chemistry
Owner
Prosecution history
- 30 Jan 2024 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 10 Jan 2024 — FINAL DISPOSITION NOTICE SENT TO IB
- 10 Jan 2024 — FINAL DISPOSITION PROCESSED
- 10 Jan 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 10 Oct 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Oct 2023 — REGISTERED-PRINCIPAL REGISTER
- 31 Aug 2023 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 20 Mar 2023 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 17 Mar 2023 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 01 Mar 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 01 Mar 2023 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 21 Feb 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Feb 2023 — PUBLISHED FOR OPPOSITION
- 20 Feb 2023 — NOTIFICATION PROCESSED BY IB
- 01 Feb 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB